Strategic Partnerships NanoMosaic has formed a co-marketing alliance with Solid Biosciences to promote Tessie platform analytics for true multi-omic capsid and transgene insights, signaling a clear path for co-sell opportunities with gene therapy developers and CMOs.

Regulatory Credibility The FDA Advanced Manufacturing Technology designation for Tessie adds third party validation, creating a compelling differentiator when engaging large biotech customers seeking validated analytics and QC capabilities in AAV manufacturing.

Market Focus The company’s emphasis on AAV gene therapy analytics and bioprocessing positions it to target early-stage gene therapy programs and contract manufacturing organizations needing comprehensive multi-omic insights.

Industry Presence Active participation in ASGCT and a newly formed Clinical Advisory Board bolster credibility and facilitate introductions to gene therapy decision-makers, accelerating market access.

Growth Levers With a lean team, modest revenue potential, and existing marketing and analytics capabilities, there are clear opportunities to expand Tessie analytics into manufacturing workflows and scale via strategic partnerships and co-marketing.